Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation

P. L. J. van der Heiden, M. S. Arbous, E. J. van Beers, W. M. van den Bergh, S. le Cessie, A. M. P. Demandt, M. Eefting, C. Hess, N. Kusadasi, W. A. F. Marijt, W. N. K. A. van Mook, M. C. A. Müller, P. R. Tuinman, M. van Vliet, D. J. van Westerloo, N. M. A. Blijlevens, Bart J. Biemond, Alexander J. Vlaar, Angelique M. Spoelstra, Murielle Hilkens & 2 others Hanneke C. Kluin, on behalf of the HEMA-ICU Study Group

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to determine short-term and long-term mortality after ICU admission of patients after alloSCT and to identify prognostic clinical and transplantation-related determinants present at ICU admission for long-term outcome. A multicenter cohort study was performed to determine 30-day and 1-year mortality within 2 years following alloSCT. A total of 251 patients were included. The 30-day and 1-year mortality was 55% and 80%, respectively. Platelet count <25 × 109/L (OR: 2.26, CI: 1.02–5.01) and serum bilirubin >19 μmol/L (OR: 2.47 CI: 1.08–5.65) at admission, other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 4.59, CI: 1.49–14.1) and vasoactive medication within 24 h (OR: 2.35, CI: 1.28–4.31) were associated with increased 30-day mortality. Other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 1.9, CI: 1.13–3.19), serum bilirubin >77 (OR: 2.05, CI: 1.28–3.30) and vasoactive medication within 24 h (OR: 1.65, CI: 1.12–2.43) were associated with increased 1-year mortality. Neutropenia was associated with decreased 30-day and 1-year mortality (OR: 0.29, CI: 0.14–0.59 and OR: 0.70, CI: 0.48–0.98). Myeloablative conditioning and T cell-depleted transplantation were not associated with increased mortality.
Original languageEnglish
Pages (from-to)418-424
JournalBone Marrow Transplantation
Volume54
Issue number3
Early online date2018
DOIs
Publication statusPublished - 1 Mar 2019

Cite this

van der Heiden, P. L. J., Arbous, M. S., van Beers, E. J., van den Bergh, W. M., le Cessie, S., Demandt, A. M. P., ... on behalf of the HEMA-ICU Study Group (2019). Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation. Bone Marrow Transplantation, 54(3), 418-424. https://doi.org/10.1038/s41409-018-0277-3
van der Heiden, P. L. J. ; Arbous, M. S. ; van Beers, E. J. ; van den Bergh, W. M. ; le Cessie, S. ; Demandt, A. M. P. ; Eefting, M. ; Hess, C. ; Kusadasi, N. ; Marijt, W. A. F. ; van Mook, W. N. K. A. ; Müller, M. C. A. ; Tuinman, P. R. ; van Vliet, M. ; van Westerloo, D. J. ; Blijlevens, N. M. A. ; Biemond, Bart J. ; Vlaar, Alexander J. ; Spoelstra, Angelique M. ; Hilkens, Murielle ; Kluin, Hanneke C. ; on behalf of the HEMA-ICU Study Group. / Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation. In: Bone Marrow Transplantation. 2019 ; Vol. 54, No. 3. pp. 418-424.
@article{0b3c3371440a43b990bcfef17eb820d3,
title = "Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation",
abstract = "Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to determine short-term and long-term mortality after ICU admission of patients after alloSCT and to identify prognostic clinical and transplantation-related determinants present at ICU admission for long-term outcome. A multicenter cohort study was performed to determine 30-day and 1-year mortality within 2 years following alloSCT. A total of 251 patients were included. The 30-day and 1-year mortality was 55{\%} and 80{\%}, respectively. Platelet count <25 × 109/L (OR: 2.26, CI: 1.02–5.01) and serum bilirubin >19 μmol/L (OR: 2.47 CI: 1.08–5.65) at admission, other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 4.59, CI: 1.49–14.1) and vasoactive medication within 24 h (OR: 2.35, CI: 1.28–4.31) were associated with increased 30-day mortality. Other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 1.9, CI: 1.13–3.19), serum bilirubin >77 (OR: 2.05, CI: 1.28–3.30) and vasoactive medication within 24 h (OR: 1.65, CI: 1.12–2.43) were associated with increased 1-year mortality. Neutropenia was associated with decreased 30-day and 1-year mortality (OR: 0.29, CI: 0.14–0.59 and OR: 0.70, CI: 0.48–0.98). Myeloablative conditioning and T cell-depleted transplantation were not associated with increased mortality.",
author = "{van der Heiden}, {P. L. J.} and Arbous, {M. S.} and {van Beers}, {E. J.} and {van den Bergh}, {W. M.} and {le Cessie}, S. and Demandt, {A. M. P.} and M. Eefting and C. Hess and N. Kusadasi and Marijt, {W. A. F.} and {van Mook}, {W. N. K. A.} and M{\"u}ller, {M. C. A.} and Tuinman, {P. R.} and {van Vliet}, M. and {van Westerloo}, {D. J.} and Blijlevens, {N. M. A.} and Biemond, {Bart J.} and Vlaar, {Alexander J.} and Spoelstra, {Angelique M.} and Murielle Hilkens and Kluin, {Hanneke C.} and {on behalf of the HEMA-ICU Study Group}",
year = "2019",
month = "3",
day = "1",
doi = "10.1038/s41409-018-0277-3",
language = "English",
volume = "54",
pages = "418--424",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

van der Heiden, PLJ, Arbous, MS, van Beers, EJ, van den Bergh, WM, le Cessie, S, Demandt, AMP, Eefting, M, Hess, C, Kusadasi, N, Marijt, WAF, van Mook, WNKA, Müller, MCA, Tuinman, PR, van Vliet, M, van Westerloo, DJ, Blijlevens, NMA, Biemond, BJ, Vlaar, AJ, Spoelstra, AM, Hilkens, M, Kluin, HC & on behalf of the HEMA-ICU Study Group 2019, 'Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation' Bone Marrow Transplantation, vol. 54, no. 3, pp. 418-424. https://doi.org/10.1038/s41409-018-0277-3

Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation. / van der Heiden, P. L. J.; Arbous, M. S.; van Beers, E. J.; van den Bergh, W. M.; le Cessie, S.; Demandt, A. M. P.; Eefting, M.; Hess, C.; Kusadasi, N.; Marijt, W. A. F.; van Mook, W. N. K. A.; Müller, M. C. A.; Tuinman, P. R.; van Vliet, M.; van Westerloo, D. J.; Blijlevens, N. M. A.; Biemond, Bart J.; Vlaar, Alexander J.; Spoelstra, Angelique M.; Hilkens, Murielle; Kluin, Hanneke C.; on behalf of the HEMA-ICU Study Group.

In: Bone Marrow Transplantation, Vol. 54, No. 3, 01.03.2019, p. 418-424.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation

AU - van der Heiden, P. L. J.

AU - Arbous, M. S.

AU - van Beers, E. J.

AU - van den Bergh, W. M.

AU - le Cessie, S.

AU - Demandt, A. M. P.

AU - Eefting, M.

AU - Hess, C.

AU - Kusadasi, N.

AU - Marijt, W. A. F.

AU - van Mook, W. N. K. A.

AU - Müller, M. C. A.

AU - Tuinman, P. R.

AU - van Vliet, M.

AU - van Westerloo, D. J.

AU - Blijlevens, N. M. A.

AU - Biemond, Bart J.

AU - Vlaar, Alexander J.

AU - Spoelstra, Angelique M.

AU - Hilkens, Murielle

AU - Kluin, Hanneke C.

AU - on behalf of the HEMA-ICU Study Group

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to determine short-term and long-term mortality after ICU admission of patients after alloSCT and to identify prognostic clinical and transplantation-related determinants present at ICU admission for long-term outcome. A multicenter cohort study was performed to determine 30-day and 1-year mortality within 2 years following alloSCT. A total of 251 patients were included. The 30-day and 1-year mortality was 55% and 80%, respectively. Platelet count <25 × 109/L (OR: 2.26, CI: 1.02–5.01) and serum bilirubin >19 μmol/L (OR: 2.47 CI: 1.08–5.65) at admission, other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 4.59, CI: 1.49–14.1) and vasoactive medication within 24 h (OR: 2.35, CI: 1.28–4.31) were associated with increased 30-day mortality. Other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 1.9, CI: 1.13–3.19), serum bilirubin >77 (OR: 2.05, CI: 1.28–3.30) and vasoactive medication within 24 h (OR: 1.65, CI: 1.12–2.43) were associated with increased 1-year mortality. Neutropenia was associated with decreased 30-day and 1-year mortality (OR: 0.29, CI: 0.14–0.59 and OR: 0.70, CI: 0.48–0.98). Myeloablative conditioning and T cell-depleted transplantation were not associated with increased mortality.

AB - Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to determine short-term and long-term mortality after ICU admission of patients after alloSCT and to identify prognostic clinical and transplantation-related determinants present at ICU admission for long-term outcome. A multicenter cohort study was performed to determine 30-day and 1-year mortality within 2 years following alloSCT. A total of 251 patients were included. The 30-day and 1-year mortality was 55% and 80%, respectively. Platelet count <25 × 109/L (OR: 2.26, CI: 1.02–5.01) and serum bilirubin >19 μmol/L (OR: 2.47 CI: 1.08–5.65) at admission, other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 4.59, CI: 1.49–14.1) and vasoactive medication within 24 h (OR: 2.35, CI: 1.28–4.31) were associated with increased 30-day mortality. Other donor than a HLA-matched-related or HLA-matched-unrelated donor (OR: 1.9, CI: 1.13–3.19), serum bilirubin >77 (OR: 2.05, CI: 1.28–3.30) and vasoactive medication within 24 h (OR: 1.65, CI: 1.12–2.43) were associated with increased 1-year mortality. Neutropenia was associated with decreased 30-day and 1-year mortality (OR: 0.29, CI: 0.14–0.59 and OR: 0.70, CI: 0.48–0.98). Myeloablative conditioning and T cell-depleted transplantation were not associated with increased mortality.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052522706&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30082850

U2 - 10.1038/s41409-018-0277-3

DO - 10.1038/s41409-018-0277-3

M3 - Article

VL - 54

SP - 418

EP - 424

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -